Panitumumab, formerly known as ABX-EGF, was the first recombinant human immunoglobulin
G2 monoclonal antibody approved by the US Food and Drug Administration for the treatment
of patients with epidermal growth factor receptor-expressing metastatic colorectal
cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing
chemotherapeutic regimens.
The purpose of this review was to evaluate the pharmacokinetic and pharmacodynamic
properties, clinical efficacy, and safety profile of panitumumab in the treatment
of metastatic colorectal cancer.
Computerized searches of MEDLINE and International Pharmaceutical Abstracts from 1985
to August 15, 2007, were performed with the search terms panitumumab, ABX-EGF, EGFr,
and colorectal cancer. All available clinical trials and ongoing trials were included
in this review. Relevant abstracts presented at the annual meetings of the American
Society of Clinical Oncology, American Association for Cancer Research, and Gastrointestinal
Cancer Symposium (1999-2007) also were reviewed and included.
Preclinical and clinical studies have established a role for panitumumab in mCRC refractory
to multiple chemotherapeutic regimens. In a Phase III trial of panitumumab plus best
supportive care (BSC) versus BSC alone in patients with refractory mCRC, panitumumab
was found to have efficacy in time-related end points, such as progression-free survival.
In the panitumumab group, a significant (46%) reduction in tumor progression rate
was reported compared with BSC (hazard ratio, 0.54; 95% CI, 0.44-0.66; P < 0.001).
At the present time, the use of panitumumab as first-line treatment for mCRC with
standard chemotherapy and bevacizumab is not indicated due to increased toxicity with
no advantage in efficacy. The efficacy of panitumumab is being evaluated in other
solid tumors, such as lung, breast, ovarian, bladder, and head and neck cancers.
Panitumumab appears to have relatively acceptable tolerability and is now available
as an additional option for patients with mCRC refractory to multiple chemotherapeutic
regimens.